Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 469.39 Million EUR | -24.46% |
| 2022 | 621.34 Million EUR | -23.98% |
| 2021 | 817.35 Million EUR | 81.97% |
| 2020 | 449.16 Million EUR | 69.67% |
| 2019 | 264.72 Million EUR | 15.14% |
| 2018 | 229.9 Million EUR | 21.42% |
| 2017 | 189.34 Million EUR | -8.48% |
| 2016 | 206.88 Million EUR | -24.82% |
| 2015 | 275.18 Million EUR | 20.95% |
| 2014 | 227.51 Million EUR | -10.56% |
| 2013 | 254.39 Million EUR | 374.02% |
| 2012 | 53.66 Million EUR | -26.57% |
| 2011 | 73.08 Million EUR | -8.07% |
| 2010 | 79.49 Million EUR | 73.0% |
| 2009 | 45.95 Million EUR | 11.04% |
| 2008 | 41.38 Million EUR | 4.55% |
| 2007 | 39.58 Million EUR | 165.27% |
| 2006 | 14.92 Million EUR | 2.2% |
| 2005 | 14.6 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 502.82 Million EUR | 7.12% |
| 2024 Q2 | 466.56 Million EUR | -7.21% |
| 2023 Q1 | 590 Million EUR | -5.04% |
| 2023 Q3 | 520.53 Million EUR | -4.06% |
| 2023 FY | 469.39 Million EUR | -24.46% |
| 2023 Q4 | 469.39 Million EUR | -9.83% |
| 2023 Q2 | 542.57 Million EUR | -8.04% |
| 2022 Q3 | 698.08 Million EUR | -3.73% |
| 2022 Q4 | 621.34 Million EUR | -10.99% |
| 2022 FY | 621.34 Million EUR | -23.98% |
| 2022 Q1 | 777.71 Million EUR | -4.85% |
| 2022 Q2 | 725.1 Million EUR | -6.76% |
| 2021 Q2 | 745.1 Million EUR | 29.78% |
| 2021 Q4 | 817.35 Million EUR | 0.0% |
| 2021 Q1 | 574.11 Million EUR | 27.82% |
| 2021 FY | 817.35 Million EUR | 81.97% |
| 2020 Q4 | 449.16 Million EUR | -0.23% |
| 2020 Q1 | 276.57 Million EUR | 4.48% |
| 2020 Q2 | 389.34 Million EUR | 40.78% |
| 2020 Q3 | 450.18 Million EUR | 15.63% |
| 2020 FY | 449.16 Million EUR | 69.67% |
| 2019 Q4 | 264.72 Million EUR | 5.62% |
| 2019 FY | 264.72 Million EUR | 15.14% |
| 2019 Q3 | 250.64 Million EUR | 0.6% |
| 2019 Q2 | 249.14 Million EUR | 2.22% |
| 2019 Q1 | 243.74 Million EUR | 6.02% |
| 2018 FY | 229.9 Million EUR | 21.42% |
| 2018 Q1 | 186.5 Million EUR | -1.5% |
| 2018 Q3 | 175.33 Million EUR | -3.38% |
| 2018 Q4 | 229.9 Million EUR | 31.12% |
| 2018 Q2 | 181.47 Million EUR | -2.7% |
| 2017 Q2 | 198.2 Million EUR | -0.19% |
| 2017 Q1 | 198.56 Million EUR | -4.02% |
| 2017 Q4 | 189.34 Million EUR | -1.24% |
| 2017 FY | 189.34 Million EUR | -8.48% |
| 2017 Q3 | 191.73 Million EUR | -3.26% |
| 2016 Q1 | 247.34 Million EUR | -10.12% |
| 2016 Q2 | 209.78 Million EUR | -15.19% |
| 2016 Q3 | 202.96 Million EUR | -3.25% |
| 2016 Q4 | 206.88 Million EUR | 1.93% |
| 2016 FY | 206.88 Million EUR | -24.82% |
| 2015 Q4 | 275.18 Million EUR | 0.32% |
| 2015 FY | 275.18 Million EUR | 20.95% |
| 2015 Q2 | 283.08 Million EUR | -2.6% |
| 2015 Q1 | 290.63 Million EUR | 27.74% |
| 2015 Q3 | 274.31 Million EUR | -3.1% |
| 2014 Q2 | 243.38 Million EUR | 0.87% |
| 2014 FY | 227.51 Million EUR | -10.56% |
| 2014 Q4 | 227.51 Million EUR | -5.36% |
| 2014 Q3 | 240.39 Million EUR | -1.23% |
| 2014 Q1 | 241.29 Million EUR | -5.15% |
| 2013 FY | 254.39 Million EUR | 374.02% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 245.27 Million EUR | 0.0% |
| 2013 Q3 | 241.9 Million EUR | -1.37% |
| 2013 Q4 | 254.39 Million EUR | 5.16% |
| 2012 Q4 | 53.66 Million EUR | 0.0% |
| 2012 Q2 | 60.44 Million EUR | 0.0% |
| 2012 FY | 53.66 Million EUR | -26.57% |
| 2011 FY | 73.08 Million EUR | -8.07% |
| 2011 Q4 | 73.08 Million EUR | 0.0% |
| 2011 Q2 | 79.35 Million EUR | 0.0% |
| 2010 FY | 79.49 Million EUR | 73.0% |
| 2010 Q4 | 79.49 Million EUR | 0.0% |
| 2010 Q2 | 54.8 Million EUR | 0.0% |
| 2009 FY | 45.95 Million EUR | 11.04% |
| 2009 Q4 | 45.95 Million EUR | 0.0% |
| 2008 FY | 41.38 Million EUR | 4.55% |
| 2007 FY | 39.58 Million EUR | 165.27% |
| 2006 FY | 14.92 Million EUR | 2.2% |
| 2005 FY | 14.6 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -3090.965% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -43.517% |
| Adocia SA | 24.95 Million EUR | -1780.874% |
| Aelis Farma SA | 26.28 Million EUR | -1686.047% |
| Biophytis S.A. | 11.93 Million EUR | -3832.565% |
| Advicenne S.A. | 12.4 Million EUR | -3683.276% |
| genOway Société anonyme | 31.84 Million EUR | -1374.108% |
| IntegraGen SA | 8 Million EUR | -5767.13% |
| Medesis Pharma S.A. | 1.92 Million EUR | -24267.049% |
| Neovacs S.A. | 47.53 Million EUR | -887.493% |
| NFL Biosciences SA | 3.97 Million EUR | -11721.581% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -3047.545% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -12427.881% |
| Sensorion SA | 46.49 Million EUR | -909.572% |
| Theranexus Société Anonyme | 7.23 Million EUR | -6385.328% |
| TME Pharma N.V. | 2.49 Million EUR | -18743.477% |
| Valbiotis SA | 33.24 Million EUR | -1311.787% |
| TheraVet SA | 7.53 Million EUR | -6130.146% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -1230.7% |
| argenx SE | 4.11 Billion EUR | 88.585% |
| BioSenic S.A. | 9.55 Million EUR | -4810.461% |
| Celyad Oncology SA | 16.28 Million EUR | -2782.883% |
| DBV Technologies S.A. | 165.65 Million USD | -183.362% |
| Galapagos NV | 4.35 Billion EUR | 89.228% |
| Genfit S.A. | 173.87 Million EUR | -169.964% |
| GeNeuro SA | 6.31 Million EUR | -7335.426% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -884.44% |
| Innate Pharma S.A. | 184.19 Million EUR | -154.837% |
| Inventiva S.A. | 69.13 Million EUR | -578.909% |
| MaaT Pharma SA | 42.93 Million EUR | -993.361% |
| MedinCell S.A. | 36.94 Million EUR | -1170.41% |
| Nanobiotix S.A. | 93.89 Million EUR | -399.9% |
| Onward Medical N.V. | 43.62 Million EUR | -975.869% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -339.093% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -473.127% |
| Oxurion NV | 6.55 Million EUR | -7066.275% |
| Pharming Group N.V. | 426.33 Million EUR | -10.098% |
| Poxel S.A. | 4.82 Million EUR | -9632.345% |
| GenSight Biologics S.A. | 9.08 Million EUR | -5065.522% |
| Transgene SA | 45.21 Million EUR | -938.085% |
| Financière de Tubize SA | 1.92 Billion EUR | 75.556% |
| UCB SA | 15.53 Billion EUR | 96.979% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -1422.563% |